Effect of rHDL on Atherosclerosis - Safety and Efficacy: THE ERASE TRIAL
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Currently available therapies to treat Acute Coronary Syndromes(ACS) have several limitations
including; the relatively long treatment duration required before apparent significant
benefit; the inability to achieve reversal of the atherosclerotic process; and poor patient
compliance due to chronicity of therapy. This study will assess the effects of rHDL compared
with placebo on indices of atherosclerosis progression and regression as assessed with
intravascular ultrasound (IVUS) in patients after acute coronary syndromes (ACS).